Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 4/20 | 0.35 |
| ▸ | PHF8 | Q9UPP1 | 4/20 | 0.35 |
| ▸ | KDM2A | Q9Y2K7 | 4/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.35 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1863195 | 0.88 | KDM5A (0.42) | KDM5APHF8KDM2AKDM4CKDM7A | |
| SCHEMBL1866585 | 0.84 | KDM5A (0.40) | KDM5APHF8KDM2AKDM4CKDM4A | |
| SCHEMBL1864017 | 0.73 | LMNA (0.43) | — | |
| SCHEMBL3591158 | 0.70 | KDM5A (0.40) | KDM5APHF8KDM2AKDM4CKDM7A | |
| SCHEMBL1863287 | 0.70 | KMT2A (0.31) | — | |
| SCHEMBL18085460 | 0.65 | HRH1 (0.30) | HRH1 | |
| SCHEMBL6917343 | 0.64 | EPHX1 (0.40) | — | |
| SCHEMBL1861192 | 0.62 | SIGMAR1 (0.52) | KDM5APHF8KDM2AKDM4CKDM4A | |
| SCHEMBL3599925 | 0.61 | KDM5A (0.42) | KDM5APHF8KDM2AKDM4CKDM4A | |
| SCHEMBL26081423 | 0.61 | SIGMAR1 (0.39) | KDM5APHF8KDM2AKDM4CKDM7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-7754737-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20090018103-A1 | Diaminoalkane Aspartic Protease Inhibitors | VITAE PHARMACEUTICAL, INC (US) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105506-A1 | Diaminoalkane aspartic protease inhibitors | DNPEP, PEPD, ACE | KDM5A 2261/4885PHF8 1652/4885KDM2A 2019/4885 |
| US-20090018103-A1 | Diaminoalkane Aspartic Protease Inhibitors | DNPEP, PEPD, ACE | KDM5A 2261/4885PHF8 1652/4885KDM2A 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.